| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $55,615,221 | 89 | 100 |
| Smith Mary L. | director | 0 | $0 | 1 | $525,060 | $-525,060 |
| Gravier Pierre | CHIEF FINANCIAL OFFICER | 0 | $0 | 3 | $652,864 | $-652,864 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | 0 | $0 | 6 | $1.08M | $-1.08M |
| Okey Stephanie | director | 0 | $0 | 2 | $1.38M | $-1.38M |
| Reeve Emma | director | 0 | $0 | 4 | $1.45M | $-1.45M |
| STEELE GLENN JR MD PHD | director | 0 | $0 | 2 | $1.7M | $-1.7M |
| Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | 0 | $0 | 5 | $1.94M | $-1.94M |
| Jacobson Allan Steven | director | 0 | $0 | 2 | $2.13M | $-2.13M |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER | 0 | $0 | 10 | $4.22M | $-4.22M |
| Boulding Mark Elliott | EXEC. VP AND CLO | 0 | $0 | 19 | $4.51M | $-4.51M |
| SCHMERTZLER MICHAEL | director | 0 | $0 | 10 | $6.62M | $-6.62M |
| Pauwels Eric | CHIEF BUSINESS OFFICER | 0 | $0 | 10 | $7.19M | $-7.19M |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 0 | $0 | 15 | $22.2M | $-22.2M |
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and …
Over the last 12 months, insiders at PTC Therapeutics, Inc. have bought $0 and sold $55.62M worth of PTC Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at PTC Therapeutics, Inc. have bought $198,736 and sold $21.89M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,700 shares for transaction amount of $198,736 was made by Gravier Pierre (CHIEF FINANCIAL OFFICER) on 2023‑12‑12.
| 2026-10-14 | Sale | SCHMERTZLER MICHAEL | director | 2,500 0.003% | $59.61 | $149,037 | +3.59% | |
| 2026-10-09 | Sale | Boulding Mark Elliott | EXEC. VP AND CLO | 192 0.0002% | $64.26 | $12,338 | -4.90% | |
| 2026-10-07 | Sale | SCHMERTZLER MICHAEL | director | 2,500 0.003% | $63.39 | $158,480 | -1.80% | |
| 2026-10-06 | Sale | Boulding Mark Elliott | EXEC. VP AND CLO | 435 0.0005% | $64.16 | $27,910 | -2.16% | |
| 2026-10-05 | Sale | Boulding Mark Elliott | EXEC. VP AND CLO | 1,638 0.002% | $64.03 | $104,881 | -1.71% | |
| 2026-09-30 | Sale | STEELE GLENN JR MD PHD | director | 12,000 0.0145% | $65.16 | $781,920 | -3.10% | |
| 2026-09-17 | Sale | SCHMERTZLER MICHAEL | director | 10,000 0.012% | $67.85 | $678,533 | -7.47% | |
| 2026-09-16 | Sale | SCHMERTZLER MICHAEL | director | 10,000 0.0119% | $67.12 | $671,195 | -6.84% | |
| 2026-09-10 | Sale | SCHMERTZLER MICHAEL | director | 10,000 0.012% | $67.34 | $673,400 | -6.29% | |
| 2026-09-09 | Sale | SCHMERTZLER MICHAEL | director | 10,000 0.012% | $67.84 | $678,403 | -6.42% | |
| 2026-08-27 | Sale | SCHMERTZLER MICHAEL | director | 12,500 0.0149% | $71.58 | $894,784 | -10.69% | |
| 2026-08-26 | Sale | SCHMERTZLER MICHAEL | director | 12,500 0.015% | $72.94 | $911,725 | -11.55% | |
| 2026-08-20 | Sale | SCHMERTZLER MICHAEL | director | 12,500 0.0151% | $71.11 | $888,858 | -8.20% | |
| 2026-08-19 | Sale | SCHMERTZLER MICHAEL | director | 12,500 0.0149% | $73.32 | $916,554 | -12.07% | |
| 2026-08-17 | Sale | Boulding Mark Elliott | EXEC. VP AND CLO | 2,813 0.0034% | $72.57 | $204,127 | -10.87% | |
| 2026-08-04 | Sale | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | 10,292 0.0122% | $68.57 | $705,722 | -4.55% | |
| 2026-07-14 | Sale | Gravier Pierre | CHIEF FINANCIAL OFFICER | 3,494 0.0043% | $80.35 | $280,743 | -12.87% | |
| 2026-07-09 | Sale | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 2,464 0.003% | $90.25 | $222,376 | -23.94% | |
| 2026-07-09 | Sale | Smith Mary L. | director | 5,834 0.0071% | $90.00 | $525,060 | -23.94% | |
| 2026-07-07 | Sale | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 24,613 0.0296% | $88.89 | $2.19M | -23.25% |
| SCHMERTZLER MICHAEL | director | 1291594 1.546% | $87.98M | 5 | 12 | +30.17% |
| Gravier Pierre | CHIEF FINANCIAL OFFICER | 83986 0.1005% | $5.72M | 1 | 7 | +25.22% |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 2441504 2.9224% | $166.32M | 1 | 1 | +8.52% |
| Koppel Adam | director | 2333333 2.7929% | $158.95M | 1 | 0 | +8.52% |
| Vulcan Ventures Inc. | director | 803067 0.9612% | $54.7M | 1 | 0 | +8.52% |
| Svoronos Dawn | 29017 0.0347% | $1.98M | 1 | 5 | +46.15% | |
| Bolte Axel | director | 20000 0.0239% | $1.36M | 1 | 0 | +8.52% |
| Rothera Mark | Chief Commercial Officer | 5125 0.0061% | $349,115.00 | 2 | 13 | +19.88% |
| ALDRICH RICHARD | director | 0 0% | $0 | 2 | 1 | +8.52% |
$67,892,722 | 138 | 28.28% | $6.25B | |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$11,583,737 | 45 | 49.75% | $4.66B | |
$477,065,869 | 34 | 82.05% | $6B |
| Increased Positions | 227 | +73.94% | 19M | +22.29% |
| Decreased Positions | 138 | -44.95% | 10M | -11.98% |
| New Positions | 99 | New | 3M | New |
| Sold Out Positions | 40 | Sold Out | 3M | Sold Out |
| Total Postitions | 396 | +28.99% | 93M | +10.31% |
| Vanguard Group Inc | $636,098.00 | 10.36% | 8.29M | -558,468 | -6.31% | 2025-09-30 |
| Rtw Investments, Lp | $594,460.00 | 9.68% | 7.75M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $547,218.00 | 8.91% | 7.13M | -349,625 | -4.67% | 2025-09-30 |
| Wellington Management Group Llp | $377,455.00 | 6.15% | 4.92M | +224,481 | +4.78% | 2025-09-30 |
| Janus Henderson Group Plc | $289,583.00 | 4.72% | 3.77M | +598,541 | +18.85% | 2025-09-30 |
| Armistice Capital, Llc | $251,498.00 | 4.1% | 3.28M | -1M | -30.79% | 2025-09-30 |
| Toronto Dominion Bank | $249,138.00 | 4.06% | 3.25M | +800,567 | +32.73% | 2025-09-30 |
| State Street Corp | $240,563.00 | 3.92% | 3.13M | +138,329 | +4.62% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $166,879.00 | 2.72% | 2.17M | -263,089 | -10.79% | 2025-09-30 |
| Geode Capital Management, Llc | $149,710.00 | 2.44% | 1.95M | +16,285 | +0.84% | 2025-09-30 |